deCODE genetics Announces Third Quarter 2007 Financi...(rability profiles in heart patients. ...)

The company will use the results from this study to inform dose

selection for a larger Phase IIb trial planned to commence early next

year. The company is at the same time advancing the reformulation of

DG031, which also targets the leukotriene pathway for the prevention of

heart attack. The company has completed an accelerated 3-month

stability study with its lead reformulation and expects to complete

pharmacokinetic analysis of its bioequivalence study before the end of

this year.

-- DG041 for arterial thrombosis. In the past quarter deCODE has

successfully completed additional clinical studies with DG041, its

novel, first in class antagonist of the EP3 receptor for prostaglandins

E2. deCODE is developing DG041 as a next-generation oral anti-platelet

therapy -- a mechanism specific means of preventing arterial thrombosis

without increasing bleeding time. Clinical studies completed early this

summer demonstrated that in a concentration-dependent manner DG041

dramatically inhibits platelet activation mediated through vasodilator-

stimulated phosphoprotein (VASP) as well as platelet aggregation.

Moreover, the desired effect on VASP -- a biomarker useful for gauging

platelet activation -- appears to be achievable at doses lower than

previously anticipated. The company has built on those results in the

past quarter with the completion of two drug-drug interaction studies

that showed DG041 to have a very satisfactory DDI profile. Moreover, in

a double-blind, placebo-controlled clinical study, DG041 was shown to

have the desired effect on VASP, and in a significant and

concentration-dependent manner, irrespective of whether subjects were

also receiving aspirin. This supports DG041's development as a compoun
'/>"/>